These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17262082)

  • 1. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
    Vincent-Salomon A; Pierga JY; Couturier J; d'Enghien CD; Nos C; Sigal-Zafrani B; Lae M; Fréneaux P; Diéras V; Thiéry JP; Sastre-Garau X
    Br J Cancer; 2007 Feb; 96(4):654-9. PubMed ID: 17262082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow.
    Schindlbeck C; Janni W; Shabani N; Rack B; Gerber B; Schmitt M; Harbeck N; Sommer H; Braun S; Friese K
    Breast Cancer Res Treat; 2004 Sep; 87(1):65-74. PubMed ID: 15377852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
    López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
    Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 gene status in primary breast cancers and matched distant metastases.
    Tapia C; Savic S; Wagner U; Schönegg R; Novotny H; Grilli B; Herzog M; Barascud AD; Zlobec I; Cathomas G; Terracciano L; Feichter G; Bubendorf L
    Breast Cancer Res; 2007; 9(3):R31. PubMed ID: 17511881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
    Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
    Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis.
    Bánkfalvi A; Giuffrè G; Ofner D; Diallo R; Poremba C; Buchwalow IB; Barresi V; Böcker W; Tuccari G
    Int J Oncol; 2003 Nov; 23(5):1285-92. PubMed ID: 14532967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
    Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas.
    Schindlbeck C; Kampik T; Janni W; Rack B; Jeschke U; Krajewski S; Sommer H; Friese K
    Breast Cancer Res; 2005; 7(6):R1174-85. PubMed ID: 16457698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.
    Park IH; Kwon Y; Ro JY; Lee KS; Ro J
    Breast Cancer Res Treat; 2010 Aug; 123(1):125-8. PubMed ID: 19916047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies.
    Amir E; Ooi WS; Simmons C; Kahn H; Christakis M; Popovic S; Kalina M; Chesney A; Singh G; Clemons M
    Clin Oncol (R Coll Radiol); 2008 Dec; 20(10):763-8. PubMed ID: 18824337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients.
    Becker S; Becker-Pergola G; Fehm T; Wallwiener D; Solomayer EF
    Anticancer Res; 2005; 25(3B):2171-5. PubMed ID: 16158960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations.
    Lambein K; Praet M; Forsyth R; Van den Broecke R; Braems G; Matthys B; Cocquyt V; Denys H; Pauwels P; Libbrecht L
    J Clin Pathol; 2011 Mar; 64(3):200-7. PubMed ID: 21177747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
    Chen PC; Yu HJ; Chang YH; Pan CC
    J Clin Pathol; 2013 Feb; 66(2):113-9. PubMed ID: 23087329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis.
    Dieci MV; Barbieri E; Bettelli S; Piacentini F; Omarini C; Ficarra G; Balduzzi S; Dominici M; Conte P; Guarneri V
    J Clin Pathol; 2012 Jun; 65(6):503-6. PubMed ID: 22389512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
    Torrisi R; Rotmensz N; Bagnardi V; Viale G; Curto BD; Dell'orto P; Veronesi P; Luini A; D'Alessandro C; Cardillo A; Goldhirsch A; Colleoni M
    Eur J Cancer; 2007 Nov; 43(16):2339-44. PubMed ID: 17855075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.